Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer.
Valdés-Mora, F
Gould, CM
Colino-Sanguino, Y
Qu, W
Song, JZ
Taylor, KM
Buske, FA
Statham, AL
Nair, SS
Armstrong, NJ
Kench, JG
Lee, KML
Horvath, LG
Qiu, M
Ilinykh, A
Yeo-Teh, NS
Gallego-Ortega, D
Stirzaker, C
Clark, SJ
- Publisher:
- NATURE PUBLISHING GROUP
- Publication Type:
- Journal Article
- Citation:
- Nat Commun, 2017, 8, (1), pp. 1346
- Issue Date:
- 2017-11-07
Open Access
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is open access.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Valdés-Mora, F | |
dc.contributor.author | Gould, CM | |
dc.contributor.author | Colino-Sanguino, Y | |
dc.contributor.author | Qu, W | |
dc.contributor.author | Song, JZ | |
dc.contributor.author | Taylor, KM | |
dc.contributor.author | Buske, FA | |
dc.contributor.author | Statham, AL | |
dc.contributor.author | Nair, SS | |
dc.contributor.author | Armstrong, NJ | |
dc.contributor.author | Kench, JG | |
dc.contributor.author | Lee, KML | |
dc.contributor.author | Horvath, LG | |
dc.contributor.author | Qiu, M | |
dc.contributor.author | Ilinykh, A | |
dc.contributor.author | Yeo-Teh, NS | |
dc.contributor.author | Gallego-Ortega, D | |
dc.contributor.author | Stirzaker, C | |
dc.contributor.author | Clark, SJ | |
dc.date.accessioned | 2022-04-13T12:26:37Z | |
dc.date.available | 2017-09-14 | |
dc.date.available | 2022-04-13T12:26:37Z | |
dc.date.issued | 2017-11-07 | |
dc.identifier.citation | Nat Commun, 2017, 8, (1), pp. 1346 | |
dc.identifier.issn | 2041-1723 | |
dc.identifier.issn | 2041-1723 | |
dc.identifier.uri | http://hdl.handle.net/10453/156218 | |
dc.description.abstract | Acetylation of the histone variant H2A.Z (H2A.Zac) occurs at active promoters and is associated with oncogene activation in prostate cancer, but its role in enhancer function is still poorly understood. Here we show that H2A.Zac containing nucleosomes are commonly redistributed to neo-enhancers in cancer resulting in a concomitant gain of chromatin accessibility and ectopic gene expression. Notably incorporation of acetylated H2A.Z nucleosomes is a pre-requisite for activation of Androgen receptor (AR) associated enhancers. H2A.Zac nucleosome occupancy is rapidly remodeled to flank the AR sites to initiate the formation of nucleosome-free regions and the production of AR-enhancer RNAs upon androgen treatment. Remarkably higher levels of global H2A.Zac correlate with poorer prognosis. Altogether these data demonstrate the novel contribution of H2A.Zac in activation of newly formed enhancers in prostate cancer. | |
dc.format | Electronic | |
dc.language | eng | |
dc.publisher | NATURE PUBLISHING GROUP | |
dc.relation.ispartof | Nat Commun | |
dc.relation.isbasedon | 10.1038/s41467-017-01393-8 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject.mesh | Acetylation | |
dc.subject.mesh | Chromatin | |
dc.subject.mesh | Disease-Free Survival | |
dc.subject.mesh | Enhancer Elements, Genetic | |
dc.subject.mesh | Epigenesis, Genetic | |
dc.subject.mesh | Gene Expression Regulation, Neoplastic | |
dc.subject.mesh | Histones | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Male | |
dc.subject.mesh | Nucleosomes | |
dc.subject.mesh | Prostatic Neoplasms | |
dc.subject.mesh | Receptors, Androgen | |
dc.subject.mesh | Chromatin | |
dc.subject.mesh | Nucleosomes | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Prostatic Neoplasms | |
dc.subject.mesh | Histones | |
dc.subject.mesh | Receptors, Androgen | |
dc.subject.mesh | Disease-Free Survival | |
dc.subject.mesh | Epigenesis, Genetic | |
dc.subject.mesh | Gene Expression Regulation, Neoplastic | |
dc.subject.mesh | Acetylation | |
dc.subject.mesh | Male | |
dc.subject.mesh | Enhancer Elements, Genetic | |
dc.title | Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer. | |
dc.type | Journal Article | |
utslib.citation.volume | 8 | |
utslib.location.activity | England | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Engineering and Information Technology | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering | |
pubs.organisational-group | /University of Technology Sydney/Centre for Health Technologies (CHT) | |
utslib.copyright.status | open_access | * |
dc.date.updated | 2022-04-13T12:26:25Z | |
pubs.issue | 1 | |
pubs.publication-status | Published online | |
pubs.volume | 8 | |
utslib.citation.issue | 1 |
Abstract:
Acetylation of the histone variant H2A.Z (H2A.Zac) occurs at active promoters and is associated with oncogene activation in prostate cancer, but its role in enhancer function is still poorly understood. Here we show that H2A.Zac containing nucleosomes are commonly redistributed to neo-enhancers in cancer resulting in a concomitant gain of chromatin accessibility and ectopic gene expression. Notably incorporation of acetylated H2A.Z nucleosomes is a pre-requisite for activation of Androgen receptor (AR) associated enhancers. H2A.Zac nucleosome occupancy is rapidly remodeled to flank the AR sites to initiate the formation of nucleosome-free regions and the production of AR-enhancer RNAs upon androgen treatment. Remarkably higher levels of global H2A.Zac correlate with poorer prognosis. Altogether these data demonstrate the novel contribution of H2A.Zac in activation of newly formed enhancers in prostate cancer.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph